Open-Label Extension (OLEX) of Studies ATH-1017-AD-0201 and ATH-1017-AD-0202 in Subjects With Mild to Moderate Alzheimer's Disease
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Fosgonimeton (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Athira Pharma
- 12 Jul 2024 Planned End Date changed from 1 Feb 2027 to 1 Sep 2028.
- 12 Jul 2024 Planned primary completion date changed from 1 Jan 2027 to 1 Aug 2028.
- 12 Jul 2024 Status changed from recruiting to active, no longer recruiting.